Menu
  • Join
  • Login
  • Contact
 

Search abstracts


A Road-to-Market Analysis for Non-Small Cell Lung Cancer Products: Tyrosine Kinase Inhibitors as a case study

  • At: 2017 FIP Congress in Stockholm (Sweden)
  • Type: Poster
  • By: DELGADO-CHARRO, M Begona (University of Bath, Pharmacy and Pharmacology, Bath, United Kingdom)
  • Co-author(s): M Begona Delgado-Charro: Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom
    Enrico Tognana: European Medicines Agency, EMA, London, United Kingdom
    Francesco Pignatti: European Medicines Agency, EMA, London, United Kingdom
    Corinne De Vries: European Medicines Agency, EMA, London, United Kingdom
  • Abstract:

    Backgrounds

    Pre- and post- submission factors influence the Road-to-Market for medicinal products.

    Aims

    This work analysed the Road-to-Market for 10 NSCLC-TKIs products for which an MAA had been submitted.

    Methods

    The choice was based on the clinical relevance and potential identification of the most significant factors in the Road-to-Market for

    ..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses